Australian Hospital to Dose Dying Patients with Synthetic Psilocybin
St Vincent's Hospital of Melbourne, Australia will begin treating patients in April
St Vincent's Hospital of Melbourne, Australia will begin treating patients in April
Seldom mentioned in scientific literature, aeruginascin is closely structurally related to psilocybin, the most well-known psychoactive compound in magic mushrooms.
The FDA will work to expedite the development and review of the drug so it can get to patients as soon as possible.
There are many compounds closely resembling psilocybin from a chemical structure standpoint. However, the chemical and pharmacological understanding of these psilocybin derivatives is few and far between.
Psilocybin gets most of the attention, and other psilocybin-like compounds present in magic mushrooms have been largely ignored.
This article explores the chemistry of blue bruising and proposes a mechanism for the chemical reaction that causes this unique effect.
The metabolism of psilocybin and psilocin is often cited. But, the supporting data are seldom discussed.
Psilocybin is showing promise for neuroregeneration and motor recovery in methods of treating phantom pain.
Recent studies on the biosynthesis of psilocybin provide an answer to this age-old question.
Magic mushrooms have multiple active components including phenethylamine. These molecules are almost never acknowledged and are probably involved the pharmacology of these fungi.
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
NEW! Shop the PSR Supporter Store to show your support for psychedelic science.